Drug Trial Radar · NCT01519791
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
880
Actual
Start
Jan 2012
Primary completion
Jul 2014
Study completion Sep 2015
Sponsor
- Lead sponsor
- UCB Pharma SAUCB
- Sponsor type
- Industry
- First posted
- Jan 27, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for inducing and sustaining clinical response in the treatment of Disease Modifying Antirheumatic Drug (DMARD)-naïve adults with early active Rheumatoid Arthritis.
Conditions
- Rheumatoid Arthritis
Interventions
Certolizumab PegolBiological
Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at a dosage strength of 200 mg/ml. Injections will be given subcutaneously. CZP 400 mg at Baseline, Week 2 and Week 4, followed by a maintenance dose of 200 mg every 2 Weeks until Week 50.
PlaceboOther
2 syringes Placebo at Baseline, Week 2 and Week 4, followed by 1 syringe Placebo every 2 Weeks.
MethotrexateBiological
The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects in Sustained Remission at Week 52Time frame: Week 52
Locations
178 sites in 22 countries. Site status is shown where the registry gives one.
209
Birmingham, Alabama
170
Huntsville, Alabama
180
Mobile, Alabama
247
Glendale, Arizona
165
Paradise Valley, Arizona
234
Paradise Valley, Arizona
243
Phoenix, Arizona
251
Tucson, Arizona
160
Covina, California
257
Hemet, California
159
Los Angeles, California
201
San Leandro, California
202
Upland, California
172
Whittier, California
190
Fort Lauderdale, Florida
196
Jupiter, Florida
238
Lake Mary, Florida
232
Miami, Florida
213
Naples, Florida
214
Ocala, Florida
237
Orange Park, Florida
255
Orlando, Florida
163
Palm Harbor, Florida
166
Plantation, Florida
192
Sarasota, Florida
200
Vero Beach, Florida
226
Coeur d'Alene, Idaho
244
Springfield, Illinois
224
South Bend, Indiana
215
Cedar Rapids, Iowa
191
Wichita, Kansas
210
Wichita, Kansas
177
Hagerstown, Maryland
199
Kalamazoo, Michigan
198
Eagan, Minnesota
203
Tupelo, Mississippi
179
St Louis, Missouri
181
Lincoln, Nebraska
256
Reno, Nevada
229
Lebanon, New Hampshire
Showing 40 of 178 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.